Moderna COVID-19 Vaccine Shows 94.1% Efficacy In Trial: Study

Moderna COVID-19 Vaccine Shows 94.1% Efficacy In Trial: Study

Moderna's COVID-19 vaccine have revealed 94.1 per cent efficacy, researchers said

New Delhi:

Results from the primary analysis of the ongoing phase 3 clinical trial of US biotechnology company Moderna's COVID-19 vaccine have revealed 94.1 per cent efficacy of the therapeutic in preventing symptomatic infections and severe illness, according to a peer-reviewed study.

The study, published on Wednesday in The New England Journal of Medicine, found that among over 30,000 participants randomised to receive the vaccine or a placebo, 11 in the vaccine group developed symptomatic COVID-19 compared to 185 participants who received the placebo.

The researchers said this demonstrates 94.1 per cent efficacy in preventing symptomatic COVID-19, adding that cases of severe disease occurred only in participants who received the placebo.

"Our work continues. Over the next months, we'll have increasing amounts of data to better define how this vaccine works, but the results so far show a 94.1 per cent efficacy. These numbers are compelling," said Lindsey Baden, an infectious diseases specialist at the Brigham and Women's Hospital in the US where the trial took place.

"And, importantly, the data suggest protection from severe illness, indicating that the vaccine could have an impact on preventing hospitalisations and deaths, at least in the first several months post-vaccination," said Ms Baden, co-principal investigator for the study, and lead author of the paper.

The study enrolled 30,420 adult participants at 99 sites in the US, including over 600 participants enrolled at the Brigham.

Eligible participants were 18 years old or more with no known history of SARS-CoV-2 infection, and whose locations or circumstances put them at appreciable risk of the infection and high risk of severe COVID-19, the researchers said.

They noted that the race and ethnicity proportion of the trial was 79 per cent white, 10 per cent Black or African American, and 20 per cent Hispanic or Latino participants.

The participants received their first injection between July 27 and October 23, followed by a second shot 28 days later.

Newsbeep


Each jab, given intramuscularly, had a volume of 0.5 millilitres (mL), containing 100 micrograms ( g) of mRNA-1273 vaccine or saline placebo.

In the placebo group, 185 participants developed symptomatic COVID-19 illness whereas in the vaccine group, only 11 participants did.

In secondary analyses, the vaccine's efficacy was similar across groups of key interest, including those who already had antibodies against SARS-CoV-2 at the time of enrolment, and among those who were 65 years of age or older, the researchers said.

Thirty participants had severe COVID-19 - all in the placebo group, they said. They were closely monitored for adverse events in the weeks following their injection.

The researchers said overall, reactions to the vaccine were mild - about half of recipients experienced fatigue, muscle aches, joint pain and headaches, more so after the second dose.

Baden said while these results are encouraging, they are limited by the short duration of follow-up so far.

"Longer term data from the ongoing study may allow us to more carefully evaluate the vaccine's efficacy among different groups, determine the impact on asymptomatic infection, understand when immunity wanes, and determine whether vaccines affect infectiousness," she added.

(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)

NDTV News

NDTV.com provides latest news from India and the world. Get today’s news headlines from Business, Technology, Bollywood, Cricket, videos, photos, live news coverage and exclusive breaking news from India.

https://www.ndtv.com/

Related news
Rep. Brian Mast gives fiery response to smear from CNN's Jake Tapper

Rep. Brian Mast gives fiery response to smear from CNN's Jake Tapper

Wounded veteran, Rep. Brian Mast, R-FL, joins 'Hannity' to discuss CNN's Jake Tapper who questioned his patriotism. #FoxNews #Hannity Subscribe to Fox News! Watch more Fox News Video: Watch Fox News Channel Live: FOX News Channel (FNC) is a 24-hou...

Virginia governor addresses security efforts in Washington metro area ahead of Inauguration Day.

Virginia governor addresses security efforts in Washington metro area ahead of Inauguration Day.

Members of Virginia's National Guard have been deployed to D.C. ahead of Inauguration Day. Troops are posted around the Capitol and other parts of Washington. Governor Ralph Northam deployed members at the request of D.C. Mayor Muriel Bowser follo...

1 21

Breaking down President-elect Joe Biden’s pandemic relief plan.

Breaking down President-elect Joe Biden’s pandemic relief plan.

ABC News Political Director Rick Klein, ABC News economic correspondent Deirdre Bolton and infectious disease specialist Dr. John Brownstein analyze Biden’s proposed $1.9 trillion COVID relief plan. ABC News Live Prime, Weekdays at 7EST & 9EST WAT...

Incoming Calif. senator: ‘There has to be accountability, nobody is above the law’

Incoming Calif. senator: ‘There has to be accountability, nobody is above the law’

California Secretary of State Alex Padilla, who will replace Vice President-elect Kamala Harris in the U.S. Senate, said he vows to fight for “what is best for California.” ABC News Live Prime, Weekdays at 7EST & 9EST WATCH the ABC News Live Strea...

Virginia governor: President ‘threw a flame on that tinder box’.

Virginia governor: President ‘threw a flame on that tinder box’.

Gov. Ralph Northam discusses the security precautions Virginia is taking in the wake of the siege on the U.S. Capitol and criticizes President Donald Trump’s rhetoric to his supporters. ABC News Live Prime, Weekdays at 7EST & 9EST WATCH the ABC Ne...

1 13

Teachers Are Using TikTok, Media To Help Students Learn Amid Pandemic - NBC News NOW.

Teachers Are Using TikTok, Media To Help Students Learn Amid Pandemic - NBC News NOW.

NBC News spoke to teachers who are using TikTok and broadcast media to engage their students amid at-home learning during the Covid-19 pandemic. » Subscribe to NBC News: » Watch more NBC video: NBC News Digital is a collection of innovative and po...